Thanks for your comments brentie and wdnering. So, maybe they are still on track if they complete the enrollments in the next couple of weeks.
From the August 7 conference call:
Hakan S. Edstrom - President and COO: Thank you Matt. Good morning. We continued to progress the combat of the clinical trials required for resubmission. We have now screened more than 87% of the patients required for Study 171 and we have screened 83% for study 175.
As we explained at the last earnings call, we have seen a higher-than-expected screen failure rate in these trials, so we’ve had to screen significantly more patient in both trials. Nonetheless, we expect screening in both studies to be completed next month.
